Diagnosing cancers of unknown primaries

By Kate McDonald
Friday, 27 February, 2009


A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.

The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.

The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.

Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.

For more information, see the March/April issue of Australian Life Scientist.

Related Articles

mRNA used to force HIV out of hiding

Using the same technology behind mRNA COVID-19 vaccines, researchers have discovered a way to...

Novel tool enables more precise gene therapy

A novel gene editor dubbed 'evoCAST' helps solve the problem of how to add long stretches...

Contact lens breakthrough lets humans see infrared light

Newly created contact lenses enable infrared vision in both humans and mice by converting...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd